Prezista Sales Data
| Rank 69 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: May 2013 (updated quarterly).
The following data shows Prezista U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q1 2013 | 69 ( 3) |
$226,038 | 4.35% | 245 | -0.41% |
| Q4 2012 | 72 (11) |
$216,609 | 10.09% | 246 | 11.31% |
| Q3 2012 | 83 ( 3) |
$196,751 | 1.17% | 221 | 0.91% |
| Q2 2012 | 80 (9) |
$194,476 | 6.35% | 219 | 5.80% |
| Q1 2012 | 89 (9) |
$182,859 | 9.20% | 207 | 4.02% |
| Q4 2011 | 98 (2) |
$167,454 | 7.73% | 199 | 7.57% |
| Q3 2011 | 100 ( ) |
$155,442 |  |
185 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| December 20, 2011 | HIV/AIDS Update - Updated Information About Prezista (Darunavir): Oral Suspension and Labeling Changes |
| December 14, 2010 | Once-Daily Dose Approved for Prezista |
